QNRX
Quoin Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · US
$7.26
−7.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 25.4K | — | — | — | — |
| Gross Profit | (25.4K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 12.5M | 9.8M | 3.6M | 3.3M | 2.7M |
| SG&A Expense | 6.7M | 6.5M | 5.9M | 6.1M | 6.6M |
| General & Admin Expense | 4.9M | 6.5M | 5.9M | 6.1M | 6.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 19.2M | 16.3M | 9.5M | 9.4M | 9.3M |
| Cost and Expenses | 19.2M | 16.3M | 9.5M | 9.4M | 9.3M |
| Operating Income (EBIT) | (19.2M) | (16.3M) | (9.5M) | (9.4M) | (9.3M) |
| Non-Operating | |||||
| Interest Income | 483.4K | 482.1K | 558.5K | 694.6K | 95.7K |
| Interest Expense | — | — | — | — | 714.1K |
| Net Interest Income | 483.4K | 482.1K | 558.5K | 694.6K | (618.3K) |
| Other Non-Op Income/Expense | 481.6K | 486.1K | 566.0K | 691.9K | (123.8K) |
| Non-Operating Income (excl Interest) | (257.1K) | (486.1K) | (566.0K) | (691.9K) | (590.3K) |
| EBT (Pre-Tax Income) | (18.8M) | (15.8M) | (9.0M) | (8.7M) | (9.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (18.8M) | (15.8M) | (9.0M) | (8.7M) | (9.4M) |
| Earnings from Cont. Ops | (18.8M) | (15.8M) | (9.0M) | (8.7M) | (9.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.8M) | (15.8M) | (9.0M) | (8.7M) | (9.4M) |
| Per Share | |||||
| Basic EPS | ($14.92) | ($10.63) | ($2,352.81) | ($11,781.00) | ($11.42) |
| Diluted EPS | ($14.92) | ($10.63) | ($2,352.81) | ($11,781.00) | ($11.42) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 2.0M | 1.5M | 3827 | 735 | 823706 |
| Diluted Shares Outstanding | 2.0M | 1.5M | 3827 | 735 | 823706 |
| Profitability Metrics | |||||
| EBITDA | (18.9M) | (15.7M) | (8.9M) | (8.6M) | (8.6M) |
| D&A | 75.4K | 100.0K | 100.0K | 103.7K | 104.0K |
| EBIT | (19.0M) | (15.8M) | (9.0M) | (8.7M) | (8.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026